Degludec insulin

also known as insulin degludec

Developed for: diabetes mellitus · diabetes mellitus, noninsulin-dependent, 2 · hyperglycemia
Investigated by: Affiliated Hospital of Jiaxing University · Affiliated Hospital of Nantong University · Affiliated Zhoushan Hospital of Wenzhou Medical University · Beijing Tsinghua Chang Gung Hospital · Chaohu Hospital of Anhui Medical University · Dongyang People's Hospital
+9 more
· Jinhua Municipal Central Hospital · Jinhua People's Hospital · King Faisal Specialist Hospital & Research Center · Taizhou First People's Hospital · The Central Hospital of Lishui City · Wenzhou Central Hospital · Wenzhou People's Hospital · Wuhu City Second People's Hospital · Yiwu Central Hospital

202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 41 trial
Phase 4	NCT06925334	May 2024 → Dec 2025 overdue	diabetes mellitus, noninsulin-dependent, 2	Beijing Tsinghua Chang Gung Hospital	Enrolling by invitation	No outcome recorded
Phase not applicable1 trial
—	NCT06056167	May 2023 → May 2024	diabetes mellitus, hyperglycemia	King Faisal Specialist Hospital & Research Center	Completed	No outcome recorded

Date	Issuer	Release
2012-08-31	Novo Nordisk A/S	Novo Nordisk A/S : Insulin degludec passerer evalueringen i japansk medicinkomite novonordisk.com ↗
2012-08-31	Novo Nordisk A/S	Novo Nordisk A/S : Insulin degludec passed the review by the First Committee on Drugs of Pharmaceutical Affairs in Japan novonordisk.com ↗

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	Degludec insulin	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06925334 ↗ 1 NCT06056167 ↗
Known as	insulin degludec	“To assess the effectiveness of using insulin degludec as basal insulin in conjunction with subcutaneous regular insulin sliding scale (ISS) in the glycemic control in...” NCT06056167 ↗
Route	Subcutaneous	“administrated subcutaneously” NCT06056167 ↗